Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rithm Capital Corp RITM

Alternate Symbol(s):  RITM.P.B

Rithm Capital Corp. is a global asset manager focused on real estate, credit and financial services. The Company’s investments in real estate related assets include its equity interest in operating companies, including origination and servicing platforms held through wholly owned subsidiaries, Newrez LLC (Newrez) and Genesis Capital LLC (Genesis), as well as investments in single-family rental (SFR), title, appraisal and property preservation and maintenance businesses. Its segments include Origination and Servicing, Investment Portfolio, Mortgage Loans Receivable, Asset Management and Corporate. The Investment Portfolio consists of mortgage servicing rights (MSR) related investments, real estate securities, properties and residential mortgage loans, consumer loans and certain ancillary investments and equity method investments. It operates its asset management business primarily through its wholly owned subsidiary, Sculptor Capital Management, Inc. (Sculptor).


NYSE:RITM - Post by User

Post by Eevhieon Feb 05, 2022 2:28am
258 Views
Post# 34400493

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS VideoFSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid-MS is an industry-first and we want to share the visual evidence of functional recovery of pre-clinical subjects in this video!
<< Previous
Bullboard Posts
Next >>